- Home
- OPRT vs FHTX Comparison
OPRT vs FHTX Comparison
Compare OPRT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- FHTX
- Stock Information
- Founded
- OPRT 2005
- FHTX 2015
- Country
- OPRT United States
- FHTX United States
- Employees
- OPRT N/A
- FHTX N/A
- Industry
- OPRT Finance: Consumer Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- OPRT Finance
- FHTX Health Care
- Exchange
- OPRT Nasdaq
- FHTX Nasdaq
- Market Cap
- OPRT 298.8M
- FHTX 271.5M
- IPO Year
- OPRT 2019
- FHTX 2020
- Fundamental
- Price
- OPRT $5.81
- FHTX $4.99
- Analyst Decision
- OPRT Hold
- FHTX Strong Buy
- Analyst Count
- OPRT 2
- FHTX 8
- Target Price
- OPRT $8.00
- FHTX $12.63
- AVG Volume (30 Days)
- OPRT 556.7K
- FHTX 121.4K
- Earning Date
- OPRT 08-06-2025
- FHTX 08-15-2025
- Dividend Yield
- OPRT N/A
- FHTX N/A
- EPS Growth
- OPRT N/A
- FHTX N/A
- EPS
- OPRT N/A
- FHTX N/A
- Revenue
- OPRT $746,101,000.00
- FHTX $23,504,000.00
- Revenue This Year
- OPRT $28.27
- FHTX $33.60
- Revenue Next Year
- OPRT $6.59
- FHTX $5.87
- P/E Ratio
- OPRT N/A
- FHTX N/A
- Revenue Growth
- OPRT N/A
- FHTX N/A
- 52 Week Low
- OPRT $2.37
- FHTX $2.95
- 52 Week High
- OPRT $9.25
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- OPRT 36.90
- FHTX 40.37
- Support Level
- OPRT $6.10
- FHTX $6.00
- Resistance Level
- OPRT $6.65
- FHTX $6.79
- Average True Range (ATR)
- OPRT 0.27
- FHTX 0.42
- MACD
- OPRT -0.06
- FHTX -0.16
- Stochastic Oscillator
- OPRT 15.15
- FHTX 3.37
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.